KRAS and squamous cell carcinoma: In 24 of the tumors we identified mutations in one or more of the above genes; one of these being a case of pleomorphic carcinoma (50% giant cell/spindle cell, 30% adenocarcinoma, 20% squamous cell carcinoma) with an EGFR mutation and another a pleomorphic carcinoma comprising solid, micropapillary and giant cell components with heterozygous allelic KRAS mutations of codon 12.